目的：研究大鼠淋巴结淋巴滤泡的生后发育。
Objective: To study the postnatal development of lymphoid follicles in rat lymph node.
目的讨论淋巴滤泡瘤样增生与滤泡性淋巴瘤的鉴别诊断。
Objective To discuss the differential diagnosis between tumor-like follicular hyperplasia and follicular lymphoma.
桥本氏病巨检与周围组织无粘连，镜检主要为淋巴滤泡形成。
The macroscopic character of hashimoto's thyroiditis is no adherence with surround-tissue and the microscopic character is lymphoid follicular formation.
淋巴细胞增生、淋巴滤泡形成、嗜酸性粒细胞和浆细胞浸润，三组间差异均无显著性。
There was no significant difference of the incidence of lymphocyte hyperplasia, lymphoid follicular formation, eosinophil and plasmacyte infiltration between the groups.
目的探讨伴有明显淋巴滤泡增生的非特指外周T细胞淋巴瘤的形态学特点和免疫表型。
Objective To investigate the morphological features and immunophenotype of unspecified peripheral t cell lymphoma with distinct lymphoid follicular growth pattern.
一种是在柱状上皮细胞组成的外分泌腺有大量淋巴细胞浸润，往往形成淋巴滤泡样结构。
One is composed of columnar epithelial cells Waibanbixian a large number of lymphocytic infiltration, often the lymphoid follicles-like structure.
在上皮处发现有喉相关淋巴组织，其中一些表现为典型的淋巴滤泡，而其它的则为聚集的淋巴细胞。
The larynx-associated lymphoid tissue (LALT) has also been observed in the epithelium, some of which exhibit as typical lymphoid follicles, and others as aggregating lymphocytes.
方法1996 ~ 2009年诊断的慢性淋巴滤泡性宫颈炎病例共8例，均采用常规观察及免疫组化染色获得正确诊断，并予以随访。
Methods to collect 8 cases with chronic follicular cervicitis between 1996 to 2009. All of cases by using he and immunohistochemistry were observed to acquire correct diagnosis, and follow-up.
结果39例儿童ITP中，有11例（28.2%）在白髓组织内出现明显的次级淋巴滤泡增生现象，而对照组为16例（57.1%）；
Results The prominent secondary follicles presented in 11 28.2% of 39 ITP cases, but only 16 57.1% in control cases.
淋巴结的滤泡中心主要是B细胞，滤泡旁区多是T细胞。
In the lymph nodes, follicular centers are primarily B cells, and parafollicular zones are primarily t cells.
滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。
The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma, which is a type of non-Hodgkin's lymphoma.
观察等待是无症状的晚期滤泡性淋巴瘤常用的策略，但是对于这些患者来说美罗华单药治疗也是一个选项。
Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicular lymphoma (FL), but single-agent rituximab is an alternative for these patients.
结论：人类滤泡树突状细胞能够增强HIV在淋巴细胞中的感染，其相关机制为FDC可促进HIV在淋巴细胞内的复制。
Conclusion: Human follicular dendritic cells can increase HIV infection in lymphocytes and the possible related mechanism is that FDC may promote HIV replication in lymphocytes.
除了代表潜在的生物标记物外，伴有缺陷BCR信号的细胞存在可提供滤泡性淋巴瘤新的靶点。
In addition to representing a potential biomarker, the existence of cells with defective BCR signaling may provide new targets against follicular lymphoma. -jcl.
目的探讨淋巴结滤泡树突状细胞肉瘤的临床和病理特点。
Objective To investigate the clinical and pathologic characteristics of the follicular dendrite cell sarcoma of lymph node.
随着滤泡及DIA的形成，T淋巴样细胞分别出现于其中。
As the follicles and DIA were forming, t lymphoid cells began to present in them.
自体干细胞移植在滤泡性淋巴瘤的一线治疗中除临床试验之外不宜采用。(证据等级：强，中等)。
Autologous stem cell transplantation has no role in first line therapy for FL outside a clinical trial (Strong, Moderate).
二期的CheckMate- 140试验正在探索用nivolumab治疗经cd 20抗体和烷化剂治疗后进展的滤泡性淋巴瘤。
The phase II CheckMate-140 trial is exploring nivolumab (Opdivo) for patients with follicular lymphoma following progression on a CD20 antibody and an alkylating agent (NCT02038946).
“这种应答率是有意义的，尽管不像霍奇金病那么高，但是依然很不错，”莱昂纳德说，“问题是，你是否专门针对滤泡性淋巴瘤来开发这种药？”
"These responses are meaningful, not as dramatic as we have seen in Hodgkin's, but it is meaningful," said Leonard. "The question is, 'can you develop this drug in follicular lymphoma?"
它包括两部分物质来源：一部分是由血淋巴通过滤泡细胞间隙向卵母细胞提供合成卵黄物质；
One is blood lymph that offers some useful materials for the oocyte to synthesize vitelline material directly through follicle cell gaps;
大部分患者将不会死于滤泡性淋巴瘤，这是非常肯定的。
Most patients will not die from follicular lymphoma, and that's very reassuring.
PI3K抑制剂idelalisib和BTK抑制剂ibrutinib对复发的滤泡性淋巴瘤显示出很好的潜力。
The PI3K deltainhibitor idelalisib (Zydelig) and the BTK inhibitor ibrutinib (Imbruvica) have shown promise for patients with relapsed follicular lymphoma.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。
Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457).
目的：研究颌面颈部血管滤泡性淋巴组织增生的临床表现、病理形态特征。
Purpose To study the clinical and pathologic features of angiofollicular lymphonode hyperplasia (AFH). Method Report two cases of this lesion.
在一个30例患者的小规模研究中，pidilizumab加利妥昔单抗在复发的滤泡性淋巴瘤中取得了66%的总有效率，其中大部分是完全缓解。
In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicular lymphoma, which primarily consisted of complete responses.
我们的研究旨在评价利妥昔单抗加化疗一线治疗的滤泡性淋巴瘤患者使用利妥昔单抗维持治疗2年的疗效。
We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.
目的系统评价大剂量化疗后自体干细胞移植一线治疗滤泡性淋巴瘤的临床疗效与安全性。
ObjectiveTo assess the effectiveness and safety of high-dose chemotherapy following autologous stem cell transplantation in first-line treatment of follicular lymphoma.
目的系统评价大剂量化疗后自体干细胞移植一线治疗滤泡性淋巴瘤的临床疗效与安全性。
ObjectiveTo assess the effectiveness and safety of high-dose chemotherapy following autologous stem cell transplantation in first-line treatment of follicular lymphoma.
应用推荐